Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of linsitinib after sorafenib failure in advanced hepatocellular carcinoma
2010-018739-17Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing linsitinib with placebo (2 arms). Primary endpoint: time to progression. Started Jun 2010; status: terminated.
02
Drugs
linsitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-018739-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018739-17.